Genetic predisposition to neural crest-derived tumors: revisiting the role of KIF1B.

endocrine tumor genetic predisposition neural crest pheochromocytoma

Journal

Endocrine connections
ISSN: 2049-3614
Titre abrégé: Endocr Connect
Pays: England
ID NLM: 101598413

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 17 09 2020
accepted: 08 10 2020
pubmed: 29 10 2020
medline: 29 10 2020
entrez: 28 10 2020
Statut: ppublish

Résumé

We previously described a family in which predisposition to pheochromocytoma (PCC) segregates with a germline heterozygous KIF1B nucleotide variant (c.4442G>A, p.Ser1481Asn) in three generations. During the clinical follow-up, one proband's brother, negative for the KIF1B nucleotide variant, developed a bilateral PCC at 31 years. This prompted us to reconsider the genetic analysis. Germline DNA was analyzed by next-generation sequencing (NGS) using a multi-gene panel plus MLPA or by whole exome sequencing (WES). Tumor-derived DNA was analyzed by SnapShot, Sanger sequencing or NGS to identify loss-of-heterozygosity (LOH) or additional somatic mutations. A germline heterozygous variant of unknown significance in MAX (c.145T>C, p.Ser49Pro) was identified in the proband's brother. Loss of the wild-type MAX allele occurred in his PCCs thus demonstrating that this variant was responsible for the bilateral PCC in this patient. The proband and her affected grandfather also carried the MAX variant but no second hit could be found at the somatic level. No other pathogenic mutations were detected in 36 genes predisposing to familial PCC/PGL or familial cancers by WES of the proband germline. Germline variants detected in other genes, TFAP2E and TMEM214, may contribute to the multiple tumors of the proband. In this family, the heritability of PCC is linked to the MAX germline variant and not to the KIF1B germline variant which, however, may have contributed to the occurrence of neuroblastoma (NB) in the proband.

Identifiants

pubmed: 33112832
doi: 10.1530/EC-20-0460
pii: EC-20-0460
pmc: PMC7707833
doi:
pii:

Types de publication

Journal Article

Langues

eng

Pagination

1042-1050

Subventions

Organisme : NCI NIH HHS
ID : P30 CA054174
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM114102
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001120
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002645
Pays : United States

Références

Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Bioinformatics. 2010 Mar 1;26(5):589-95
pubmed: 20080505
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Cell. 2001 Jun 1;105(5):587-97
pubmed: 11389829
Mod Pathol. 2018 Jun;31(6):974-983
pubmed: 29410489
J Mol Diagn. 2017 Jul;19(4):575-588
pubmed: 28552549
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
Nat Biotechnol. 2009 Feb;27(2):182-9
pubmed: 19182786
N Engl J Med. 2019 Aug 8;381(6):552-565
pubmed: 31390501
J Mol Diagn. 2019 Jul;21(4):646-657
pubmed: 31201024
Curr Protoc Bioinformatics. 2013;43:11.10.1-11.10.33
pubmed: 25431634
Hum Genet. 2008 Oct;124(3):279-85
pubmed: 18726616
Bioinformatics. 2019 Jun 1;35(11):1978-1980
pubmed: 30376034
Nat Rev Endocrinol. 2017 Apr;13(4):233-247
pubmed: 27857127
Cancer Discov. 2014 Apr;4(4):434-51
pubmed: 24469107
Am J Clin Pathol. 1991 Feb;95(2):117-24
pubmed: 1846996
J Biol Chem. 2008 Sep 5;283(36):24426-34
pubmed: 18614535
Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15497-501
pubmed: 25313051
Genes Chromosomes Cancer. 2006 Jan;45(1):83-93
pubmed: 16215979
J Clin Endocrinol Metab. 2014 Jul;99(7):E1352-60
pubmed: 24694336
Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W590-4
pubmed: 15215457
Eur J Med Genet. 2017 Mar;60(3):178-184
pubmed: 28089742
Clin Cancer Res. 2012 May 15;18(10):2828-37
pubmed: 22452945
Genes Dev. 2008 Apr 1;22(7):884-93
pubmed: 18334619

Auteurs

Catherine Cardot Bauters (C)

CHU Lille, Service d'Endocrinologie, Diabétologie, Métabolisme-Nutrition, Hôpital Claude Huriez, Lille, France.

Emmanuelle Leteurtre (E)

Univ. Lille, Inserm, CHU Lille, UMR-S 1277-CANTHER, Cancer Heterogeneity, Plasticity & Resistance to Therapies, Lille, France.

Bruno Carnaille (B)

CHU Lille, Service de Chirurgie Endocrine, Hôpital Claude Huriez, Lille, France.

Christine Do Cao (C)

CHU Lille, Service d'Endocrinologie, Diabétologie, Métabolisme-Nutrition, Hôpital Claude Huriez, Lille, France.

Stéphanie Espiard (S)

CHU Lille, Service d'Endocrinologie, Diabétologie, Métabolisme-Nutrition, Hôpital Claude Huriez, Lille, France.

Malo Penven (M)

CHU Lille, Service de Biochimie Hormonologie, Métabolisme, Nutrition-Oncologie, Centre de Biologie Pathologie Génétique, Lille, France.

Evelyne Destailleur (E)

CHU Lille, Service de Biochimie Hormonologie, Métabolisme, Nutrition-Oncologie, Centre de Biologie Pathologie Génétique, Lille, France.

Isabelle Szuster (I)

CHU Lille, Service de Biochimie Hormonologie, Métabolisme, Nutrition-Oncologie, Centre de Biologie Pathologie Génétique, Lille, France.

Tonio Lovecchio (T)

CHU Lille, Service de Biochimie Hormonologie, Métabolisme, Nutrition-Oncologie, Centre de Biologie Pathologie Génétique, Lille, France.

Julie Leclerc (J)

Univ. Lille, Inserm, CHU Lille, UMR-S 1277-CANTHER, Cancer Heterogeneity, Plasticity & Resistance to Therapies, Lille, France.
CHU Lille, Service de Biochimie Hormonologie, Métabolisme, Nutrition-Oncologie, Centre de Biologie Pathologie Génétique, Lille, France.

Fredéric Frénois (F)

Univ. Lille, CHU Lille, EA-7364 RADEME, Faculté de Médecine, Lille, France.

Emmanuel Esquivel (E)

Dept Medicine, Mays Cancer Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.

Patricia L M Dahia (PLM)

Dept Medicine, Mays Cancer Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.

Emilie Ait-Yahya (E)

CHU Lille, Institut de Biochimie & Biologie Moléculaire, Centre de Biologie Pathologie Génétique, Lille, France.

Michel Crépin (M)

CHU Lille, Service de Biochimie Hormonologie, Métabolisme, Nutrition-Oncologie, Centre de Biologie Pathologie Génétique, Lille, France.

Pascal Pigny (P)

CHU Lille, Service de Biochimie Hormonologie, Métabolisme, Nutrition-Oncologie, Centre de Biologie Pathologie Génétique, Lille, France.

Classifications MeSH